<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="shortcut icon" href="../images/favicon.png" type="image/x-icon">
  <title>Insulin and Insulin Preparations</title>
  <link href="https://cdn.jsdelivr.net/npm/remixicon@2.5.0/fonts/remixicon.css" rel="stylesheet">
  <link rel="stylesheet" href="../style.css">
  <link rel="stylesheet" href="../notes.css">

</head>
<body>
  <input type="checkbox" id="main-navigation-toggle" class="btn btn--close" title="Toggle main navigation" />
  <label for="main-navigation-toggle">
    <span></span>
  </label>
  
  <a href="../index.html">
   <div class="home-navigation">
      mtr<span class="logo-dot">.</span>
    </div>
  </a>


    <nav id="main-navigation" class="nav-main">
    <ul class="menu">
      <li class="menu__item">
        <a class="menu__link" href="../index.html">Home</a>
      </li>

      <li class="menu__item">
        <a class="menu__link" href="../about-temp2.html">About</a>
      </li>
    </ul>
  </nav>
  
      <!-- Toggle switch for dark mode -->
      <div class="dark-mode-toggle">
        <label class="switch-toggle">
            <input type="checkbox" id="dark-mode-toggle-checkbox">
            <span class="toggle-slider"></span>
        </label>
      </div>

      <!-- Progress Bar  -->
      <div id="progress-container">
        <div id="progress-bar"></div>
    </div>
      
<!-- SIDEBAR -->
<div id="sidebar" class="sidebar">
  <button id="closeSidebarBtn" class="btn toggle-btn close-btn">Close</button>
  <ul class="sidebar-menu toggle-menu">
    <!-- Add the list of topics dynamically using JavaScript -->
  </ul>
</div>

<!-- Toggle button to open the sidebar -->
<button id="toggleSidebarBtn" class="btn toggle-btn">&#9776;</button>

<!-- END OF SIDEBAR -->

  <main class="page-container">
    <div class="contribute-cta">
      <p>Help make this betterüíú</p>
      <span><a href="../contribute.html">Contribute here</a> </span>
    </div>


  <!-- TOPIC AND IMAGE CONTAINER  -->


      <h1>Insulin and Insulin Preparations</h1>


  <!-- END OF TOPIC AND IMAGE CONTAINER  -->
  


    <article class="notes">
        <a id='top'></a>
    <article>

          <!-- LEARNING OBJECTIVES CONTAINER  -->
              <div class="custom-card" id="custom-card-1">
                <div class="icon"><img src="../images/icons/light-bulb.png" alt="Icon" class="icon"></div>
                <div class="title"> 
                  <h2>What You Will Learn</h2>
                </div>
                <div class="line">
                  <p>After reading this note, you should be able to...</p>
                </div>
                <div class="content">
                  <ul>
                    <li><i>This content is not available yet.</i></li>
                </ul>
                </div>
                <div class="read-more" onclick="toggleContent('custom-card-1')">Read More üç™</div>
              </div>
            
          <!-- END OF LEARNING OBJECTIVES CONTAINER  -->
        
        
          <!-- SHOW AND HIDE OUTLINE CONTAINER  -->
            <div class="outline2">
        
              <input type="radio" name="control-2" id="show-2">
              <label for="show-2">üêµ&nbsp; &nbsp;Show Outline</label>
              <input type="radio" name="control-2" id="hide-2">
              <label for="hide-2">üôà&nbsp; &nbsp; Hide Outline</label>
              <div class="contents">
                <div class="icon-box">
                  <!-- Replace 'path/to/your/icon.png' with the actual path to your PNG icon -->
                  <img src="../images/icons/book.png" alt="Icon" class="icon">
                </div>
                <div id="tableOfContents">
                    <ol id="tocList"></ol>
                </div>
              </div>
             <div>
        
        <!-- END OF SHOW AND HIDE OUTLINE CONTAINER  -->
        
        
        <!-- READ SUMMARY CONTAINER -->
        
              <!-- Summary Overlay -->
              <div class="summary-overlay" id="summaryOverlay"></div>
        
        
              <div class="summary-card" id="summaryCard">
                
                <div class="summary-header">
                  <h3>Note Summary</h3>
                  <div class="icon-box">
                    <!-- Replace 'path/to/your/icon.png' with the actual path to your PNG icon -->
                    <img src="../images/icons/summary.png" alt="Icon" class="icon">
                  </div>
                </div>
                <div class="summary-content">
                  <!-- Summary content goes here -->
                  <p><i>This content is not available yet.</i></p>
        
                  <span class="close-btn" id="closeBtn">close</span>
                </div>
              </div>
        
              <div class="summary-trigger" id="summaryTrigger">
                <p>Click here to read a summary</p>
            </div>
        <!-- END OF READ SUMMARY CONTAINER -->
        
            <!-- BEGINNING OF NOTE -->
        
      <section id='header-1'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-1'>Introduction</a>
          </h2>
        </header>
        <div class='body'>
            <h4>Diabetes Mellitus Type 1</h4>
            <p><strong>Diabetes mellitus type 1</strong> is due to <strong>insulin deficiency</strong>. Treatment involves <strong>dietary modification</strong> plus <strong>insulin administration</strong>.</p>
            
            <h4>Diabetes Mellitus Type 2</h4>
            <p><strong>Diabetes mellitus type 2</strong> is due to <strong>reduced secretion of insulin</strong> or <strong>insulin resistance</strong> (lack of sensitivity of target organs to insulin). Treatment involves <strong>dietary modification</strong> with or without <strong>oral hypoglycemic agents</strong> and/or <strong>insulin</strong>.</p>
            
        </div>
      </section>

      <section id='header-2'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-2'>Actions and Effects</a>
          </h2>
        </header>
        <div class='body'>
            <p><strong>Insulin</strong> binds with and activates receptors on the cell membranes of most body cells. Target tissues include the <strong>liver</strong>, <strong>muscle</strong>, and <strong>adipose tissue</strong>. After insulin-receptor binding occurs, cell membranes become highly permeable and allow entry of <strong>glucose</strong>, <strong>amino acids</strong>, <strong>fatty acids</strong>, and <strong>potassium</strong>. This results in the following effects:</p>
            
            <ol>
              <li>
                <strong>Reduction in Blood Glucose Due To:</strong>
                <ul>
                  <li>
                    <strong>a)</strong> Increased glucose uptake in peripheral tissues (which oxidize glucose or convert it to glycogen or fat).
                  </li>
                  <li>
                    <strong>b)</strong> Decreased hepatic output of glucose by reducing glycogenolysis and gluconeogenesis.
                  </li>
                </ul>
              </li>
            
              <li>
                <strong>Anabolic Effects:</strong>
                <ul>
                  <li>
                    In muscles and most other cells, insulin facilitates amino acid uptake and their synthesis into proteins, as well as inhibits protein breakdown, resulting in decreased amino acid output (precursors for hepatic gluconeogenesis).
                  </li>
                  <li>
                    In adipose tissue, insulin inhibits lipolysis and favors triglyceride synthesis.
                  </li>
                </ul>
              </li>
            
              <li>
                <strong>Suppression of Ketogenesis (Ketone Body Synthesis) By:</strong>
                <ol>
                  <li>
                    <strong>a)</strong> Inhibiting lipolysis in adipose tissues and release of free fatty acids; the major source for hepatic ketogenesis.
                  </li>
                  <li>
                    <strong>b)</strong> Suppressing hepatic oxidation of free fatty acids to ketone bodies.
                  </li>
                </ol>
              </li>
            
              <li>
                <strong>Stimulation of K<sup>+</sup> Entry Into Cells By Stimulating Na<sup>+</sup>/K<sup>+</sup> ATPase Action.</strong>
              </li>
            </ol>
            
        </div>
      </section>

      <section id='header-3'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-3'>Sources of Commercial Insulin Preparations</a>
          </h2>
        </header>
        <div class='body'>
            <ul>
              <li>Pork or beef pancreas.</li>
              <li>Human insulin: made either by enzymatic modification of porcine insulin or by using recombinant DNA technology (e.g., soluble insulin).</li>
              <li>Human insulin analogues: made by modifying the amino acid sequence of the human insulin molecule to produce insulin preparations with different onset and durations of action but similar pharmacodynamics effects (e.g., insulin lispro and insulin glargine).</li>
            </ul>
            
        </div>
      </section>

      <section id='header-4'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-4'>Pharmacokinetics</a>
          </h2>
        </header>
        <div class='body'>
            <p><strong>Insulin cannot be taken orally because</strong> it is a peptide and digested in the gastrointestinal tract.</p>
            
            <p><strong>Main Route of Administration:</strong> Subcutaneous but can be given intravenously (IV) and intramuscularly (IM).</p>
            
            <p><strong>It is cleared out of circulation rapidly because of</strong> binding to peripheral tissues and metabolism in the liver, kidneys, muscles, and plasma, and excreted by kidneys. The plasma <strong>half-life (t<sub>1/2</sub>)</strong> is 5-9 minutes.</p>
            
            <h4>Factors Affecting Subcutaneous Absorption:</h4>
            <ul>
              <li><strong>Site:</strong> The abdomen has the fastest rate of absorption, followed by the arms, thighs, and buttocks.</li>
              <li><strong>Massage of injection site, exercise, and heat application</strong> increase absorption, probably by increasing blood flow to the skin.</li>
              <li>Areas of <strong>lipohypertrophy</strong> usually show slower absorption rates.</li>
            </ul>
            
            <h4>Dose and Daily Insulin Requirement in Diabetics:</h4>
            <p>Daily pancreatic secretion is 30-40 units, and most insulin-deficient diabetics need 30-50 units of insulin per day. The standard strength (amount) of insulin in vials is 100 units/ml.</p>
            
        </div>
      </section>

      <section id='header-5'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-5'>Insulin Preparations</a>
          </h2>
        </header>
        <div class='body'>

            <ol>
              <li>
                <strong>Short-acting:</strong> (e.g., soluble insulin)
                <ul>
                  <li>Clear solution.</li>
                  <li>Onset of action is 30 minutes after subcutaneous injection, so it needs to be injected 30 minutes before the main meals to control early postprandial hyperglycemia.</li>
                  <li>Duration of action is 8 hours, thus requiring frequent administration.</li>
                  <li>Can be given intravenously (IV): acts faster and can be given in high doses for the treatment of:
                    <ul>
                      <li>ketoacidosis: Ketone bodies inhibit glucose uptake by the brain and muscle.</li>
                      <li>Acute short-term insulin resistance (insulin requirement increases > 200 U/day) due to infection, trauma, surgery, emotional stress; where corticosteroids and other hormones are produced in excess as a reaction to stress and oppose insulin actions.</li>
                      <li>Hyperkalemia.</li>
                    </ul>
                  </li>
                </ul>
              </li>
            
              <li>
                <strong>Rapid-acting insulin:</strong> (e.g., insulin lispro)
                <ul>
                  <li>Clear solution of modified human insulin.</li>
                  <li>Onset of action is very rapid (within 15 minutes) after subcutaneous injection; can be injected immediately before or even after the meal to control postprandial hyperglycemia.</li>
                  <li>Duration of action is 5 hours. This decreases the risk of late post-meal hypoglycemia.</li>
                </ul>
              </li>
              <li>
                <strong>Intermediate-acting insulin:</strong> (e.g., NPH - Neutral Protamine Hagedorn) (isophane insulin)
                <ul>
                  <li>Cloudy neutral suspension of insulin with an equivalent amount of Protamine, a basic protein that delays absorption and prolongs the duration of action of insulin.</li>
                  <li>Onset of action is 1.5 hours and duration of action is 12 hours.</li>
                </ul>
              </li>
            
              <li>
                <strong>Long-acting insulin:</strong> (e.g., insulin glargine)
                <ul>
                  <li>Clear solution, has an acidic pH. When administered subcutaneously, insulin precipitates at the neutral pH in tissues at the injection site then dissociates slowly to enter the circulation.</li>
                  <li>Onset of action is delayed (1.5 hours), so it does not control postprandial hyperglycemia, but relatively low peakless continuous blood levels of insulin are maintained for up to 24 hours. Thus, it is suitable for once-daily administration.</li>
                  <li>Should not be mixed with other forms of insulin in the same syringe to avoid disturbance of its pH and loss of efficacy.</li>
                </ul>
              </li>
            
              <li>
                <strong>Biphasic insulin:</strong> a premixed combination of fast and long- or intermediate-acting insulin (e.g., insulin mixtard that contains 30% soluble insulin plus 70% NPH insulin).
              </li>
            </ol>
            

<br>
            <table class="note-table">
              <thead>
                <tr>
                    <th colspan="5" style="text-align: center;">Short-Acting Insulins</th>
                </tr>
                <tr>
                  <th>Insulin</th>
                  <th>Preparation</th>
                  <th>Use</th>
                  <th>Duration</th>
                  <th>Notes</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td>Soluble (Neutral) <br> e.g. Hypurin¬Æ</td>
                  <td>Highly-purified porcine or bovine</td>
                  <td>DM, DKA, Surgery</td>
                  <td>Rapid onset (30-60 min).<br>Peak 2-4 hrs. <br>Duration 8 hrs.</td>
                  <td>All routes of administration.</td>
                </tr>
                <tr>
                  <td>Soluble (Neutral) <br> e.g. Humulin¬Æ, Insuman¬Æ</td>
                  <td>Human-sequence modified porcine</td>
                  <td>DM, DKA, Surgery</td>
                  <td>Rapid onset (30-60 min).<br>Peak 2-4 hrs.<br>Duration 8 hrs.</td>
                  <td>Not indicated for use in S/C infusion.</td>
                </tr>
                <tr>
                  <td>Aspart</td>
                  <td>Recombinant human insulin analogue</td>
                  <td>DM</td>
                  <td>Faster onset.<br>Shorter duration.</td>
                  <td>Less hypoglycemic events.</td>
                </tr>
                <tr>
                  <td>Glulisine</td>
                  <td>Recombinant human insulin analogue</td>
                  <td>DM</td>
                  <td>Faster onset.<br>Shorter duration.</td>
                  <td>Less hypoglycemic events.</td>
                </tr>
                <tr>
                  <td>Lispro</td>
                  <td>Recombinant human insulin analogue</td>
                  <td>DM</td>
                  <td>Faster onset.<br>Shorter duration.</td>
                  <td>Less hypoglycemic events.</td>
                </tr>
              </tbody>
            </table>
            
            <br>

            <table class="note-table">
              <thead>
                <tr>
                    <th colspan="5" style="text-align: center;">Intermediate- and Long-Acting Insulins</th>
                </tr>
                <tr>
                  <th>Insulin</th>
                  <th>Preparation</th>
                  <th>Use</th>
                  <th>Duration</th>
                  <th>Notes</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td>Detemir <br>e.g. Levemir¬Æ</td>
                  <td>Recombinant human insulin analogue</td>
                  <td>DM</td>
                  <td>Long-acting.<br>Delayed onset 1-2 hrs.<br>Peak 4-12 hrs.<br>Duration 16-35 hrs.</td>
                  <td>Should not be mixed with soluble insulin in the same syringe.<br>Once daily (OD) or twice daily (BID) with soluble insulin.</td>
                </tr>
                <tr>
                  <td>Glargine <br> e.g. Lantus¬Æ</td>
                  <td>Recombinant human insulin analogue</td>
                  <td>DM</td>
                  <td>Long-acting.<br>Delayed onset 1-2 hrs.<br>Peak 4-12 hrs.<br>Duration 16-35 hrs.</td>
                  <td>Should not be mixed with soluble insulin in the same syringe.<br>OD or BID with soluble insulin.</td>
                </tr>
                <tr>
                  <td>Insulin zinc suspension (Mixed) <br> e.g. Hypurin¬Æ Bovine Lente</td>
                  <td>Human-sequence or porcine and/or bovine insulin complexed with a suitable zinc salt</td>
                  <td>DM</td>
                  <td>Long-acting.<br>Delayed onset 1-2 hrs.<br>Peak 4-12 hrs.<br>Duration 16-35 hrs.</td>
                  <td></td>
                </tr>
                <tr>
                  <td>Isophane insulin <br>(Isophane protamine insulin injection)</td>
                  <td>Porcine or bovine insulin or Human-sequence suspension complexed with a suitable protamine</td>
                  <td>DM</td>
                  <td>Intermediate-acting</td>
                  <td></td>
                </tr>
                <tr>
                  <td>Protamine Zinc Insulin</td>
                  <td>Soluble insulin complexed with protamine and zinc chloride</td>
                  <td>DM</td>
                  <td>Long-acting.</td>
                  <td>Blunts the initial effect of soluble insulins.</td>
                </tr>
              </tbody>
            </table>
            
            <br>

            <table class="note-table">
              <thead>
                <tr>
                    <th colspan="4" style="text-align: center;">Biphasic Insulins</th>
                </tr>
                <tr>
                  <th>Insulin</th>
                  <th>Preparation</th>
                  <th>Use</th>
                  <th>Duration</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td>Biphasic insulin Lispro <br> e.g. Humalog¬Æ Mix</td>
                  <td>25% insulin Lispro, 75% insulin Lispro protamine</td>
                  <td>DM</td>
                  <td>Intermediate-acting</td>
                </tr>
                <tr>
                  <td>Biphasic insulin Aspart <br> e.g. Novomix¬Æ</td>
                  <td>30% Insulin Aspart, 70% Insulin Aspart protamine</td>
                  <td>DM</td>
                  <td>Intermediate-acting</td>
                </tr>
                <tr>
                  <td>Biphasic Isophane insulin <br> e.g. Mixtard¬Æ</td>
                  <td>Porcine or human insulin complexed with protamine sulfate in a solution of insulin of the same species</td>
                  <td>DM</td>
                  <td>Intermediate-acting</td>
                </tr>
              </tbody>
            </table>
            
            
        </div>
      </section>

      <section id='header-6'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-6'>Side Effects</a>
          </h2>
        </header>
        <div class='body'>
            <ol>
              <li><strong>Hypoglycemia:</strong> If not treated, it may progress to coma.</li>
              <li><strong>Lipodystrophy (hypertrophy or atrophy) of subcutaneous fatty tissues at injection site:</strong> Can be prevented by advising the patient to change sites within the injection area.</li>
              <li><strong>Allergy:</strong> Urticaria and anaphylaxis due to immune reactions to animal insulin preparations or additive proteins. Bovine insulin is more antigenic than porcine insulin.</li>
              <li><strong>Local reactions:</strong> Swelling and erythema.</li>
              <li><strong>Insulin resistance:</strong> Due to antibodies against animal insulin or additive proteins. Insulin requirement may increase > 200 U/day. Switching to human insulin can reduce resistance.</li>
            </ol>
            
        </div>
      </section>








      <hr style="margin: 3rem 0;">

      <!-- PRACTICE QUESTIONS CONTAINER -->

      <div class="custom-card" id="custom-card-2">
        <div class="icon"><img src="../images/icons/practice-questions.png" alt="Icon" class="icon"></div>
        <div class="title"> 
          <h2>Practice Questions</h2>
        </div>
        <div class="line">
          <p>Check how well you grasp the concepts by answering the following questions...</p>
        </div>
        <div class="content">
          <ol>
            <li><i>This content is not available yet.</i></li>
          </ol>
        </div>
        <div class="read-more" onclick="toggleContent('custom-card-2')">Read More üç™</div>
      </div>

      <!-- END OF PRACTICE QUESTIONS CONTAINER -->


      <!-- CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
      <div class="contact">
        <div class="comment-container">
          <div class="comment-icon">
            <!-- Add your icon image here -->
            <img src="../images/icons/comment.png" alt="Comment Icon">
          </div>
          <div class="comment-text">
            <!-- Add your text here -->
            <p>Send your comments, corrections, explanations/clarifications and requests/suggestions </p>
          </div>
          <a href="https://chat.whatsapp.com/FtDdb6uEFYzBCnTnMgm2Z1" class="comment-button">
            here
            <img src="../images/icons/whatsapp.png" alt="Image Icon">
          </a>
        </div>

        <div class="contributors-container">

          <h2 class="contributors-header">Contributors</h2>
  
        <br>
            <div class="contributor-box">
                <img class="contributor-avatar" src="../images/icons/woman.png" alt="Contributor 1 Avatar">
                <div class="contributor-info">
                    <h3 class="contributor-name">Jane Smith</h3>
                    <p class="contributor-description">She is not a real contributor.</p>
                    <div class="social-links">
                        <a href="#" target="_blank" class="social-icon">
                            <img src="../images/icons/whatsapp.png" alt="Social Icon 1">
                        </a>
                        <a href="#" target="_blank" class="social-icon">
                            <img src="../images/icons/twitter.png" alt="Social Icon 2">
                        </a>
                    </div>
                </div>
            </div>
        
            <div class="contributor-box">
                <img class="contributor-avatar" src="../images/icons/man.png" alt="Contributor 2 Avatar">
                <div class="contributor-info">
                    <h3 class="contributor-name">John Doe</h3>
                    <p class="contributor-description">He is not a real contributor.</p>
                    <div class="social-links">
                      <a href="#" target="_blank" class="social-icon">
                        <img src="../images/icons/whatsapp.png" alt="Social Icon 1">
                    </a>
                    <a href="#" target="_blank" class="social-icon">
                        <img src="../images/icons/linkedin.png" alt="Social Icon 2">
                    </a>
                    </div>
                </div>
            </div>
        
        </div>
      </div>

            <!-- END OF CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
    </article>
   </article>
   <div style="height: 300px;"></div>
  </main>

  <footer>
    <div class="footer-container">
        <div>
          <p id="popup-trigger">disclaimer</p>

          <!-- The pop-up dive content -->
          <div id="popup" class="popup">
            <p>The contents on this ‚Äòwebsite‚Äô are for educational purposes only. The creators and operators of this website make no warranties, express or implied, regarding the accuracy, currency, or completeness of the information provided on the website. They shall not be held responsible for any errors or omissions, or for any actions taken based on the information provided on this website.</p>
            <button class="popup-close" onclick="closePopup()">Close</button>
          </div>    
          <p><a href="../about-temp2.html">about</a> </p>   
          <p><a href="../contribute.html">contribute</a> </p>
          <p><a href="https://chat.whatsapp.com/FtDdb6uEFYzBCnTnMgm2Z1">say hiüëã</a> </p>
        </div>

        <div class="footer-beta">
          <p>thisisatestversion</p>
        </div>
    </div>
  </footer>
<!------------  SCROLL UP ----------->
<a href="#" class="scrollup" id="scroll-up"> 
  <i class="ri-arrow-up-fill scrollup__icon"></i>
</a>
<script src="../main.js"></script>
<script src="../modal.js"></script>
<script src="../notes-sidebar.js"></script>
</body>
</html>
 
